Alimera Sciences (NASDAQ:ALIM) Stock Price Passes Above 200-Day Moving Average of $3.64

Alimera Sciences, Inc. (NASDAQ:ALIM) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.64 and traded as high as $3.73. Alimera Sciences shares last traded at $3.67, with a volume of 51,634 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. StockNews.com downgraded Alimera Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Maxim Group started coverage on Alimera Sciences in a report on Monday, March 25th. They set a “buy” rating and a $10.00 price objective for the company.

Alimera Sciences Stock Up 5.2 %

The business’s fifty day simple moving average is $3.72 and its 200 day simple moving average is $3.64. The stock has a market cap of $192.12 million, a price-to-earnings ratio of -1.70 and a beta of 1.18. The company has a current ratio of 2.39, a quick ratio of 2.31 and a debt-to-equity ratio of 1.40.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.09). The company had revenue of $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter in the prior year, the business earned ($0.54) earnings per share. Equities analysts forecast that Alimera Sciences, Inc. will post 0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alimera Sciences

Several institutional investors have recently modified their holdings of ALIM. Worth Venture Partners LLC bought a new position in Alimera Sciences during the 3rd quarter worth approximately $1,840,000. AIGH Capital Management LLC acquired a new stake in Alimera Sciences in the third quarter worth $7,355,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Alimera Sciences during the third quarter worth $12,349,000. 99.83% of the stock is currently owned by institutional investors and hedge funds.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).